<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1890">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136560</url>
  </required_header>
  <id_info>
    <org_study_id>DEXA-SEPSIS</org_study_id>
    <nct_id>NCT05136560</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Early Administration of Dexamethasone in High-risk Sepsis</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center Clinical Trial to Evaluate the Safety and Efficacy of Early Administration of Dexamethasone in High-risk Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHA University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHA University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of early administration&#xD;
      of two different doses of dexamethasone in high risk septic patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The septic adult patients of high risk would be enrolled in 2 emergency departments.&#xD;
&#xD;
      Sepsis would be defined by Sepsis-3 definition. High risk is defined as initial systolic&#xD;
      blood pressure less than 90 mmHg or blood lactate level over 2 mmol/L.&#xD;
&#xD;
      The enrolled patients would be randomized to 3 groups: control, low dose dexamethasone (0.1&#xD;
      mg/kg iv), and high dose dexamethasone (0.2mg/kg iv).&#xD;
&#xD;
      The study drug is blinded and administered after enrollment for 2 days. Sample size would be&#xD;
      102, considering 10% of drop-out rate, allocating 30 patients to each groups.&#xD;
&#xD;
      Efficacy would be evaluated as follows; 28 day and 90 day mortality, time to septic shock,&#xD;
      time to shock reversal, administration of steroid according to guideline, ventilator free&#xD;
      days, Continuous renal replacement, Length of stay in ICU or hospital, delta SOFA score on&#xD;
      day 3 and day 7,&#xD;
&#xD;
      Safety would be evaluated as follows; Hyperglycemia, Hypernatremia, Hyperchloremia,&#xD;
      Hypertension, Bleeding, Encephalopathy, Leukocytosis, Myopathy, Septic arthritis, Ischemia&#xD;
      bowel, Would problem, Circulatory shock, Thrombocytopenia,&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>28 days</time_frame>
    <description>death at 28 day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>90 day mortality</measure>
    <time_frame>90 days</time_frame>
    <description>death at 90 day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to septic shock</measure>
    <time_frame>up to 1 month, During hospital stay</time_frame>
    <description>Time to septic shock after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to shock reversal</measure>
    <time_frame>up to 1 month, During hospital stay</time_frame>
    <description>time required for shock reversal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of steroid according to guideline, yes or no</measure>
    <time_frame>up to 1 month, During hospital stay</time_frame>
    <description>Need for additional steroid requirement according to the sepsis guideline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilator free days</measure>
    <time_frame>up to 3 month, During hospital stay</time_frame>
    <description>days independent from ventilator care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>continuous renal replacement therapy (CRRT)</measure>
    <time_frame>up to 3 month, During hospital stay</time_frame>
    <description>requirement of CRRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care unit (ICU)</measure>
    <time_frame>up to 6 month, During hospital stay</time_frame>
    <description>Days spent in intensive care unit (ICU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>up to 6 month, During hospital stay</time_frame>
    <description>Days spent in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta SOFA sore on day 3 and 7</measure>
    <time_frame>7 days</time_frame>
    <description>Change of SOFA score on day 3 and day 7</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mg/kg dexamethasone iv once per day, for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2 mg/kg dexamethasone iv once per day, for 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Intervention drugs would be administered for 2 days.</description>
    <arm_group_label>high dose dexamethasone</arm_group_label>
    <arm_group_label>low dose dexamethasone</arm_group_label>
    <other_name>JEIL Dexamethasone Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sepsis defined by Sepsis-3 definition&#xD;
&#xD;
          -  Initial systolic blood pressure &lt; 90mmHg or blood lactate level &gt;2mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  advanced directive for &quot;Do not resuscitation&quot;&#xD;
&#xD;
          -  recent systemic administration of glucocorticoid (4 weeks)&#xD;
&#xD;
          -  recent systemic administration of chemotherapy (4 weeks)&#xD;
&#xD;
          -  recent systemic administration of immunosuppressant (4 weeks)&#xD;
&#xD;
          -  expected life less than 90 days&#xD;
&#xD;
          -  Transferred from other hospital&#xD;
&#xD;
          -  Sepsis diagnosed 24 hours after ED admission&#xD;
&#xD;
          -  recent GI bleeding, 6 weeks&#xD;
&#xD;
          -  Traumatic brain injury or stroke, within 3 months&#xD;
&#xD;
          -  Use of etomidate in ED&#xD;
&#xD;
          -  operation, within 72 hours&#xD;
&#xD;
          -  multiple trauma, within 72 hours&#xD;
&#xD;
          -  severe thrombocytopenia, &lt;30,000/mm3)&#xD;
&#xD;
          -  severe chronic liver disease, Child-Pugh score C&#xD;
&#xD;
          -  hemophilia&#xD;
&#xD;
          -  pregnant or on lactation&#xD;
&#xD;
          -  no informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHA University</investigator_affiliation>
    <investigator_full_name>Kyuseok Kim</investigator_full_name>
    <investigator_title>Professor, Emergency Department</investigator_title>
  </responsible_party>
  <keyword>sepsis, glucocorticoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

